Impact of a donor source on adult philadelphia chromosome-negative acute lymphoblastic leukemia: A retrospective analysis from the adult acute lymphoblastic leukemia working group of the japan society for hematopoietic cell transplantation

Annals of Oncology

Volumn 24, Issue 6, 2013, Pages 1594-1602

  Nishiwaki, S ^a   Miyamura, K ^b   Ohashi, K ^c   Kurokawa, M ^d   Taniguchi, S ^e   Fukuda, T ^f   Ikegame, K ^g   Takahashi, S ^h   Mori, T ⁱ   Imai, K ^j   Iida, H ^k   Hidaka, M ^l   Sakamaki, H ^c   Morishima, Y ^m   Kato, K ^b   Suzuki, R ^a   Tanaka, J ⁿ  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^c TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^d UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^e TORANOMON HOSPITAL   (Japan)

^f NATIONAL CANCER CENTER   (Japan)

^g HYOGO COLLEGE OF MEDICINE   (Japan)

^h UNIVERSITY OF TOKYO   (Japan)

ⁱ KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j SAPPORO HOKUYU HOSPITAL   (Japan)

^k Meitetsu Hospital   (Japan)

^l NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

^m AICHI CANCER CENTER HOSPITAL   (Japan)

ⁿ HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Allogeneic stem cell transplantation; Cord blood; Donor source; Philadelphia chromosome negative acute lymphoblastic leukemia

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DRB1 ANTIGEN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CYTOGENETICS; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MOLECULAR TYPING; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; WHOLE BODY RADIATION;

EID: 84878438842     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds655     Document Type: Article

References (54)

1. Rowe JM, Buck G, Burnett AK et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005; 106: 3760-3767.
2. Kantarjian H, Thomas D, O'Brien S et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004; 101: 2788-2801.
3. Gokbuget N, Hoelzer D, Arnold R et al. Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am 2000; 14: 1307-1325, ix.
4. Larson RA, Dodge RK, Burns CP et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995; 85: 2025-2037.
5. Linker C, Damon L, Ries C et al. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol 2002; 20: 2464-2471.
6. Annino L, Vegna ML, Camera A et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002; 99: 863-871.
7. Thomas X, Boiron JM, Huguet F et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004; 22: 4075-4086.
8. Takeuchi J, Kyo T, Naito K et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 2002; 16: 1259-1266.
9. Nishiwaki S, Inamoto Y, Imamura M et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in complete remission. Blood 2011; 117: 3698-3699.
10. Goldstone AH, Richards SM, Lazarus HM et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008; 111: 1827-1833.
11. Marks DI, Perez WS, He W et al. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood 2008; 112: 426-434.
12. Nishiwaki S, Inamoto Y, Sakamaki H et al. Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission. Blood 2010; 116: 4368-4375.
13. Kako S, Morita S, Sakamaki H et al. A decision analysis of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission who have an HLA-matched sibling donor. Leukemia 2011; 25: 259-65.
14. Marks DI, Wang T, Perez WS et al. The outcome of full intensity and reduced intensity conditioning matched sibling or unrelated donor (URD) transplantation in adults with Philadelphia chromosome negative acute lymphoblastic leukemia (PHALL) in first and second complete remission (CR1 and CR2). Blood 2010; 116: 366-74.
15. Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
16. Sullivan KM, Shulman HM, Storb R et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267-276.
17. Sasazuki T, Juji T, Morishima Y et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med 1998; 339: 1177-1185.
18. Morishima Y, Sasazuki T, Inoko H et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 2002; 99: 4200-4206.
19. Atsuta Y, Morishima Y, Suzuki R et al. Comparison of unrelated cord blood transplantation and HLA-mismatched unrelated bone marrow transplantation for adults with leukemia. Biol Blood Marrow Transplant 2012; 18: 780-787.
20. Matsuno N, Wake A, Uchida N et al. Impact of HLA disparity in the graft-versushost direction on engraftment in adult patients receiving reduced-intensity cord blood transplantation. Blood 2009; 114: 1689-1695.
21. Ooi J, Takahashi S, Tomonari A et al. Unrelated cord blood transplantation after myeloablative conditioning in adults with acute myelogenous leukemia. Biol Blood Marrow Transplant 2008; 14: 1341-1347.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
23. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc A 1972; 135: 185-207.
24. Gooley TA, Leisenring W, Crowley J et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
25. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 2007; 40: 381-387.
26. Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34: 187-220.
27. Gallardo D, de la Camara R, Nieto JB et al. Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study. Haematologica 2009; 94: 1282-1288.
28. Anasetti C, Logan BR, Lee SJ et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367: 1487-1496.
29. Oh H, Loberiza FR, Jr, Zhang MJ et al. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood 2005; 105: 1408-1416.
30. Baker KS, Loberiza FR, Jr, Yu H et al. Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States. J Clin Oncol 2005; 23: 7032-7042.
31. Laughlin MJ, Eapen M, Rubinstein P et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351: 2265-2275.
32. Rocha V, Labopin M, Sanz G et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351: 2276-2285.
33. Takahashi S, Iseki T, Ooi J et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 2004; 104: 3813-3820.
34. Barker JN, Weisdorf DJ, DeFor TE et al. Transplantation of 2 partially HLAmatched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 105: 1343-1347.
35. Rocha V, Crotta A, Ruggeri A et al. Double cord blood transplantation: extending the use of unrelated umbilical cord blood cells for patients with hematological diseases. Best Pract Res Clin Haematol 2010; 23: 223-229.
36. Brunstein CG, Gutman JA, Weisdorf DJ et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010; 116: 4693-4699.
37. Frassoni F, Gualandi F, Podesta M et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol 2008; 9: 831-839.
38. Brunstein CG, Barker JN, Weisdorf DJ et al. Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units. Bone Marrow Transplant 2009; 43: 935-940.
39. Frassoni F, Varaldo R, Gualandi F et al. The intra-bone marrow injection of cord blood cells extends the possibility of transplantation to the majority of patients with malignant hematopoietic diseases. Best Pract Res Clin Haematol 2010; 23: 237-244.
40. Delaney C, Heimfeld S, Brashem-Stein C et al. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010; 16: 232-236.
41. Kelly SS, Sola CB, de Lima M et al. Ex vivo expansion of cord blood. Bone Marrow Transplant 2009; 44: 673-681.
42. Matsumura T, Kami M, Yamaguchi T et al. Allogeneic cord blood transplantation for adult acute lymphoblastic leukemia: retrospective survey involving 256 patients in Japan. Leukemia 2012; 26: 1482-1486.
43. Ooi J, Iseki T, Takahashi S et al. Unrelated cord blood transplantation for adult patients with de novo acute myeloid leukemia. Blood 2004; 103: 489-491.
44. Sanz J, Sanz MA, Saavedra S et al. Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia. Biol Blood Marrow Transplant 2010; 16: 86-94.
45. Ooi J, Iseki T, Takahashi S et al. Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome. Blood 2003; 101: 4711-4713.
46. Sato A, Ooi J, Takahashi S et al. Unrelated cord blood transplantation after myeloablative conditioning in adults with advanced myelodysplastic syndromes. Bone Marrow Transplant 2011; 46: 257-261.
47. Sanz J, Montesinos P, Saavedra S et al. Single-unit umbilical cord blood transplantation from unrelated donors in adult patients with chronic myelogenous leukemia. Biol Blood Marrow Transplant 2010; 16: 1589-1595.
48. Robin M, Sanz GF, Ionescu I et al. Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT. Leukemia 2011; 25: 75-81.
49. Rodrigues CA, Sanz G, Brunstein CG et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009; 27: 256-263.
50. Eapen M, Rocha V, Sanz G et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010; 11: 653-660.
51. Atsuta Y, Suzuki R, Nagamura-Inoue T et al. Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood 2009; 113: 1631-1638.
52. Tomblyn MB, Arora M, Baker KS et al. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. J Clin Oncol 2009; 27: 3634-3641.
53. Mehta J. Hematopoietic stem cell transplantation from unrelated donors for acute leukemia. Blood 2008; 112: 447-448.
54. Nishiwaki S, Miyamura K. Allogeneic stem cell transplant for adult Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Lymphoma 2012; 53: 550-556.